相关实验视频
Updated: May 9, 2026

07:47
Experimental Human Pneumococcal Carriage
Published on: February 15, 2013
15.4K
在罗马尼亚儿科国家免疫计划中实施20肺炎球菌合疫苗的成本效益分析
Alin Preda1, An Ta2, Elizabeth Vinand2
1Pfizer Romania, Bucharest, Romania.
Journal of medical economics
|April 30, 2025
概括
在罗马尼亚,切换到20肺炎球菌合疫苗 (PCV20).
科学领域:
- 公共卫生 公共卫生
- 疫苗学 疫苗学 疫苗学
- 卫生经济学 卫生经济学
背景情况:
- 罗马尼亚面临着肺炎球菌病的重大负担,尽管目前的儿科疫苗接种计划.
- 像PCV20这样的高性肺炎球菌合疫苗 (PCV) 比现有疫苗 (PCV13,PCV15) 提供更广泛的血清型覆盖.
研究的目的:
- 评估将20肺炎球菌合疫苗 (PCV20) 引入罗马尼亚国家免疫计划的成本效益.
- 从社会角度来看,将PCV20与当前的13价值PCV (PCV13) 和潜在的15价值PCV (PCV15) 相比较.
主要方法:
- 基于人口的多队列马尔科夫模型被用于模拟2岁以下儿童在10年内的影响.
- 分析采用了罗马尼亚的社会视角,包括直接和间接成本.
- 进行了敏感性和场景分析,以确保模型的稳定性.
主要成果:
- PCV20在PCV13和PCV15上都表现出主导地位,因为它更有效,成本更低.
- 该模型预测,与PCV13相比,成本节约超过7900万罗恩,与PCV15相比,成本节约超过2.6亿罗恩.
- 预计肺炎球菌病例将减少246,245例 (与PCV13相比) 和223,914例 (与PCV15相比).
结论:
- 在罗马尼亚国家儿科免疫计划中实施PCV20是一种具有成本效益的战略.
- 预计PCV20将在10年内从社会角度显著减少肺炎球菌疾病的负担.
关键词:
第115章 在这里在I1818年,在PCV13中使用PCV13.在PCV15中使用PCV15.在PCV20中使用PCV20罗马尼亚 罗马尼亚 罗马尼亚 罗马尼亚经济效益性 经济效益性国家免疫计划国家免疫计划儿科 儿科 儿科肺炎球菌联合疫苗接种接种疫苗 接种疫苗更多相关视频
11:32Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
Published on: February 23, 2014
15.0K
09:14An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay
Published on: January 26, 2019
10.7K
相关概念视频
Vaccinations
Overview
Drug Dosing: Infants and Children
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Pharmacokinetics in Pediatric Patients: Drug Distribution
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Metabolism
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Excretion
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Antimicrobial Effectiveness
The effectiveness of antimicrobial agents depends on various factors influencing their ability to eliminate microbial populations. Larger microbial populations require more time for complete eradication, emphasizing the importance of population size analysis when evaluating antimicrobial efficacy.Microbial resistance to antimicrobial agents varies significantly. Highly resilient microorganisms include endospores, gram-negative bacteria, and non-enveloped viruses, while prions are exceptionally...